ProCE Banner Events

Share

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

Join us in person for this live 1-hour workshop series on how the community care team can integrate CDK4/6 inhibitors into adjuvant treatment of early-stage breast cancer. Get up to date on identifying eligible patients, supporting adherence, and managing toxicities.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Who Should Attend

This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

Time and location

Tuesday, June 11, 2024

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

Faculty
Jane Lowe Meisel, MD

Associate Professor of Hematology and Medical Oncology
Associate Vice Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, Georgia

Agenda

  • Integrating Adjuvant CDK4/6 Therapy for Appropriate Patients With HR-Positive/HER2-Negative EBC in Your Practice
  • Strategies for Promoting Adherence and Persistence to Oral Therapy in Your Practice
  • Considerations for the Multidisciplinary Team

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in applying current data on the use of CDK4/6 inhibitors as part of their care of patients with early-stage breast cancer.

Target Audience
This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

Learning Objectives
At the conclusion of this activity, learners should be better able to:

  • Identify patients who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting

  • Plan evidence-based personalized treatment strategies for HR-positive/HER2-negative early breast cancer, fostering collaborative discussions and workflows among the oncology multidisciplinary team

  • Develop strategies that promote optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer

  • Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-028-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.